Nanobiotix (NBTX) Competitors $7.19 +0.29 (+4.20%) Closing price 08/7/2025 03:54 PM EasternExtended Trading$7.44 +0.24 (+3.41%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, DYN, SANA, and RCUSShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), Dyne Therapeutics (DYN), Sana Biotechnology (SANA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Sana Biotechnology Arcus Biosciences Cidara Therapeutics (NASDAQ:CDTX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Which has more risk and volatility, CDTX or NBTX? Cidara Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Do analysts rate CDTX or NBTX? Cidara Therapeutics presently has a consensus target price of $57.29, indicating a potential downside of 7.20%. Nanobiotix has a consensus target price of $8.00, indicating a potential upside of 11.27%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings and valuation, CDTX or NBTX? Nanobiotix has higher revenue and earnings than Cidara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M979.90-$169.83M-$29.47-2.09Nanobiotix$39.18M8.65-$73.73MN/AN/A Does the media favor CDTX or NBTX? In the previous week, Cidara Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Cidara Therapeutics and 0 mentions for Nanobiotix. Cidara Therapeutics' average media sentiment score of 0.86 beat Nanobiotix's score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cidara Therapeutics Positive Nanobiotix Neutral Is CDTX or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -73.04% -54.28% Nanobiotix N/A N/A N/A Do institutionals and insiders believe in CDTX or NBTX? 35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.9% of Cidara Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCidara Therapeutics beats Nanobiotix on 8 of the 14 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$325.22M$2.51B$5.48B$9.56BDividend YieldN/A1.78%3.99%4.17%P/E RatioN/A19.6629.9325.14Price / Sales8.65425.10375.2276.13Price / CashN/A165.0335.9458.58Price / Book-4.764.198.105.59Net Income-$73.73M$31.61M$3.26B$265.48M7 Day Performance6.76%0.95%0.68%1.22%1 Month Performance32.41%2.90%2.45%0.39%1 Year Performance51.37%4.11%27.72%23.47% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix0.8266 of 5 stars$7.19+4.2%$8.00+11.3%+53.6%$325.22M$39.18M0.00100Gap UpCDTXCidara Therapeutics3.3764 of 5 stars$62.68+1.3%$57.29-8.6%+456.1%$1.25B$1.27M-2.1390News CoverageEarnings ReportCVACCureVac4.4619 of 5 stars$5.42-0.7%$6.83+26.1%+64.5%$1.22B$579.18M5.89880News CoverageUpcoming EarningsAUPHAurinia Pharmaceuticals2.1475 of 5 stars$8.89-0.4%$11.50+29.4%+114.8%$1.21B$235.13M31.75300Insider TradePRAXPraxis Precision Medicines1.6654 of 5 stars$55.65-6.0%$94.11+69.1%-9.1%$1.21B$8.12M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0935 of 5 stars$28.92-0.9%$24.40-15.6%+60.8%$1.18B$1.02B37.081,940Positive NewsAnalyst RevisionSRPTSarepta Therapeutics4.6235 of 5 stars$13.86+16.2%$51.42+271.0%-87.2%$1.17B$1.90B-5.151,372Trending NewsEarnings ReportAnalyst ForecastDYNDyne Therapeutics3.3786 of 5 stars$9.31-6.4%$40.63+336.4%-73.5%$1.13BN/A-2.59100Upcoming EarningsAnalyst ForecastSANASana Biotechnology3.3016 of 5 stars$4.88-1.4%$9.17+87.8%-37.1%$1.12BN/A-5.55380News CoverageUpcoming EarningsGap DownRCUSArcus Biosciences2.1011 of 5 stars$9.85-3.7%$21.29+116.1%-33.4%$1.08B$258M-2.35500Earnings ReportAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Cidara Therapeutics Competitors CureVac Competitors Aurinia Pharmaceuticals Competitors Praxis Precision Medicines Competitors Calliditas Therapeutics AB (publ) Competitors Phibro Animal Health Competitors Sarepta Therapeutics Competitors Dyne Therapeutics Competitors Sana Biotechnology Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBTX Stock Alerts